Clinical Trial 24097-B

• Overview

  Study Title:

  Phase 2, Randomized, Prospective, Open-Label, Parallel-Arm, Dose Optimization Study to Investigate the Safety, Tolerability, PK/PD, and Anti-Tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

• Treatments

  Therapies:

  PARP inhibitor

  Medications:

  2X-121 ()

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.